PDB19 TIME TO OPIOID USE AND HEALTH CARE COSTS AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS  by Zhao, Y et al.
A404 Paris Abstracts
from the budget of both payers would raise by 579.5 thousand PLN (130.3 thousand 
a) in 2009 and 1.2 mln PLN (261 thousand a) in 2010. Depending on parameter 
changes, the budget would change by o 17% and o19% for NHS and both payers 
perspective, respectively. CONCLUSIONS: The reimbursement of vildagliptin will 
cause the raise of NHF expenses by 0.37% in 2009 and 0.70% in 2010 of the budget 
spent for oral drugs reimbursed in diabetes mellitus. For both payers’ perspective, the 
reimbursement of vildagliptin will cause the raise expenses by 0.27% in 2009 and 
0.53% in 2010 of the budget.
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OBJECTIVES: To estimate the health care direct costs of an episode of extensive 
superﬁcial or deep uncomplicated foot ulcer of neuropathic origin in patients with 
diabetes in Spain and identify the key factors that inﬂuence total costs. METHODS: 
A retrospective observational study of patients with an episode of foot ulcer during 
the period from January 2007 through December 2008 in 10 Spanish centres was 
performed. Data about sociodemographic characteristics, duration of the episode and       
health care-related resources were considered. The following resources were collected      
from hospital records: inpatient hospitalisations, surgeries, outpatient visits (specialists 
and primary care physician), diagnostic procedures, laboratory tests, ulcer-related 
cures, antibiotics and orthotic devices. Unitary cost (a, year 2009 values) data were 
taken from a Spanish Database of Health Costs and the Catalogue of Medicinal 
Products. RESULTS: Ninety-two patients (29.3% with one or more previous ulcers) 
with a foot ulcer episode were identiﬁed. The majority of cases were males (76.9%).        
Patients’ mean age was 65.20 o 10.90 years and 50.0% of these were retired. Average      
duration of an ulcer episode was 131 o 123 days. Most prevalent comorbidities were 
arterial hypertension (62.0% of cases), diabetic retinopathy (41.3%), renal impair-
ment (30.4%), dyslipidemias (25.0%) and myocardial infarction (19.6%). Concomi-
tant infections during the episode were reported in 33.7% of patients. The average 
cost per patient and ulcer episode was a17,262 (95% conﬁdence interval [CI], 
a11,315, a23,715). The most important categories of costs were for surgeries (a7054, 
95%CI, a6043–a8200, 40.9% of costs), inpatient hospitalisations (a6197, 95%CI, 
a3605–a8878, 35.9% of total costs), and ulcer-related cures (a2864, 95%CI, a1127–
a4759, 16.6% of total costs). Among surgeries, the most relevant were debridements 
and amputations. CONCLUSIONS: An episode of a neuropathic extensive superﬁcial 
or deep uncomplicated diabetic foot ulcer generates a substantial economic burden, 
with a mean cost per patient of a17,262. Surgeries, hospitalisations and ulcer-related 
cures represent 93.4% of total costs.
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OBJECTIVES: Poor glycemic control is associated with increased morbidity and 
mortality among hospitalized patients. Insulin aspart may be more effective in achiev-
ing glycemic control than human insulin. This study compares glycemic control, length 
of stay (LOS), hospital mortality, and charges for hospitalized patients receiving 
insulin aspart or human bolus insulin. METHODS: This study is a retrospective 
analysis of the Health Facts® database (Cerner Corporation, Kansas City, MO). 
Health Facts is a unique database built from hospital comprehensive clinical records 
including pharmacy, laboratory, emergency room, admission, and billing information 
from hospitals throughout the United States, all time-stamped and sequenced. The 
sample included 36,991 medical patients with discharge dates from January 1, 2004 
through December 31, 2007. Patients were segmented into those who exclusively 
received insulin aspart (n  4605, 12.5%) or human (n  32386, 87.6%) bolus insulin. 
Outcomes of interest included blood glucose (BG) control (overall mean BG  140 mg/
dL), length of stay (LOS), in-patient mortality, and hospital charges (in $2007). 
Results were compared with t-tests or chi-square tests. RESULTS: Insulin aspart 
patients demonstrated better blood glucose control (34.22% vs. 30.78% with mean 
BG  140 mg/dL, p  0.001) even though they experienced increased illness as dem-
onstrated by higher Charlson comorbidity scores (2.0 (1.7) vs. 1.9 (1.8), p  0.001) 
and had more heart, kidney, and lung diseases diagnosed during their stay. Insulin 
aspart was also associated with shorter LOS (5.5 (5.4) vs. 6.3 (6.8) p  0.001), lower 
mortality (3.8% vs. 8.7%, p  0.001) and fewer total charges ($25,074 (28,775) vs. 
$33,472 (41704), p  0.001). CONCLUSIONS: Insulin aspart patients appeared to 
have better glycemic control, shorter LOS, lower mortality and reduced hospital 
charges than patients on human bolus insulin. Multivariate adjustments are needed 
to conﬁrm these ﬁndings but the unadjusted results suggest insulin aspart is associated 
with better outcomes than human bolus insulin.
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OBJECTIVES: To estimate treatment costs attributable to overweight or obese status 
in diabetic patients in the U.S.A. METHODS: The data was drawn from the 2003–
2006 Medical Expenditure Panel Survey. Adult patients (18–74 years-old) with dia-
betes were identiﬁed based on a self-reported diagnosis or ICD-9-CM code of 250. 
Patients with pregnancy, malignancy, kidney dialysis, immunodeﬁciency, or body-
mass-index (BMI) 18.5 were excluded. Medical treatment costs included ofﬁce based 
physician/outpatient visits, emergency room visits, or hospitalizations, excluding 
dental problems and injuries. The treatment costs attributable to being overweight 
(25 a BMI  30) or obese (BMI q 30) at various points of the cost distribution were 
estimated using weighted quantile regression after controlling for demographics, 
comorbidities, and other study variables. Treatment costs attributable to being over-
weight/obese were calculated by the differences in the actual treatment costs for over-
weight/obese patients and the expected costs if obese patients were normal-weight 
patients using the study variable coefﬁcients obtained from all patients. All costs were 
converted to 2006 U.S. dollars using price indices. Data were analyzed using SAS and 
SUDAAN. RESULTS: A total of 5338 patients with diabetes were selected for this 
study. Approximately 88% of the diabetic patients were overweight (31%) or obese 
(57%). Compared with normal-weight patients, the incremental treatment costs attrib-
utable to obesity were signiﬁcantly higher by $35, $96, $196, $290, and $739 at the 
10th, 25th, 50th, 75th, and 90th percentiles, respectively. Similar trends were found in 
overweight patients compared with those of normal-weight, but the attributable costs 
were not signiﬁcantly different except at the 75th percentile point. CONCLUSIONS: 
The overall economic burdens attributable to being overweight and obese in diabetic 
patients were substantial and increased signiﬁcantly in the upper tail of the treatment 
cost distribution. The important ﬁnding that the magnitude of attributable costs 
increased across the distribution of treatment costs would not have been possible 
without the quantile regression method.
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OBJECTIVES: The clinical effectiveness of exenatide and glargine is well established 
for the treatment of type 2 diabetes (T2D). However, the relative economic and utiliza-
tion impact of these therapies is uncertain. This study examined the cost offsets associ-
ated with the use of exenatide compared to glargine in patients with T2D. METHODS: 
A retrospective analysis was conducted using a large, managed care claims database. 
Adult patients with T2D who had initiated either exenatide (N  9264) or glargine 
(N  3791) therapy between April 1, 2005 and June 30, 2007 with pre- (6 months) 
and post-index (12 months) continuous eligibility were included. Annual mean total 
medical costs and several mean cost components were estimated using propensity score 
stratiﬁcation to control for baseline demographic, clinical and resource utilization 
variables. Mean costs were estimated using nonparametric bootstrapping. RESULTS: 
Exenatide-treated patients had signiﬁcantly lower total direct medical ($20,792 vs. 
$24,954, p  0.0001), inpatient ($4,836 vs. $6,966, p  0.0001), outpatient ($9,510 
vs. $11,858, p  0.0001), and emergency room (ER) costs ($96 vs. $131, p  0.04). 
Exenatide-treated patients had higher total prescription costs ($6349 vs. $6000, 
p  0.0004). Furthermore, exenatide-treated patients had signiﬁcantly lower costs of 
hospitalization ($4802 vs. $6873, p  .0001) mainly due to lower macrovascular 
complications ($1620 vs. $2661, p  0.001), and also lower ofﬁce visit costs ($3317 
vs. $4176, p  0.0001) and hospital outpatient visits ($5144 vs. $6608, p  0.0001) 
compared to glargine-treated patients. Although prescription costs of exenatide was 
higher than glargine ($1544 vs. $843, p  0.0001), exenatide-treated patients incurred 
signiﬁcantly lower costs of concomitant antidiabetic medications ($1283 vs. $1415, 
p  0.0001) and other prescription medications ($3235 vs. $3438, p  0.015) com-
pared to glargine-treated patients. CONCLUSIONS: Patients who initiated exenatide 
treatment had signiﬁcantly lower total medical costs mainly due to lower inpatient, 
outpatient and ER visits despite having higher total prescription costs. Although, the 
index-drug costs were higher for exenatide, cost savings were observed in hospitaliza-
tions, ofﬁce visits, and hospital outpatient visits.
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OBJECTIVES: To compare the use of opioids and health care costs between patients 
with diabetic peripheral neuropathic pain (DPNP) who initiated treatment with dulox-
etine versus other standard of care DPNP treatments. METHODS: This retrospective 
cohort study analyzed administrative claims database 2004–2006 from a large US 
commercially-insured population to assess opioid utilization and health care costs over 
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a one-year follow-up period. DPNP patients aged 18–64 years initiated on duloxetine 
(Dulox) or other standard of care (SOC) therapies, including tricyclic, venlafaxine, 
gabapentin, and pregabalin, between March 1, 2005 and December 31, 2005 were 
selected. Initiation of treatment was deﬁned as no pill coverage over the prior 90 days. 
The ﬁrst observed prescription claim denoted as the “index date”. SOC patients were 
randomly matched (ratio 1:1) to Dulox patients via propensity score matching control-
ling for patient demographics, clinical characteristics, and prior health care utilization. 
Opioid utilization and health care costs were compared between matched study 
cohorts. RESULTS: Propensity score matching resulted in 112 Dulox and 112 SOC 
patients. Compared with SOC patients, Dulox patients were less likely to use any 
DPNP-related opioids (52.7% vs. 82.1%, p  0.01). Patients who initiated duloxetine 
had 2.0 fewer opioids prescription dispensed (p  0.01) and 32 fewer days on opioids 
(p  0.01) than those in the SOC cohort. Patients in the Dulox cohort were initiated 
on opioids approximately four months later than SOC patients (p  0.01). The cumula-
tive opioid dose in morphine equivalents were signiﬁcantly lower for Dulox patients 
than SOC patients (833 mg vs. 3,114 mg, p  0.01). Dulox cohort had signiﬁcantly 
lower total health care costs than SOC cohort ($22,273 vs. $34,785, p  0.05), primar-
ily due to lower outpatient costs ($7,567 vs. $17,584, p  0.01). CONCLUSIONS: 
Duloxetine treatment appears to be associated with delayed use of opioids among 
patients with DPNP. Health care costs were also lower for patients initiated on 
duloxetine vs. SOC treatment.
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OBJECTIVES: From a German health care perspective, to evaluate the cost per patient 
in achieving KDOQITM targets with the use of a combination of cinacalcet  traditional 
therapy (TT). METHODS: The number of patients eligible for cinacalcet was derived 
from the OPen-label, Randomized Study Using Cinacalcet HCL To IMprove Achieve-
ment of KDOQITM Targets in Patients With End-Stage Renal Disease (OPTIMA) Trial 
[1], assessing the efﬁcacy of adding cinacalcet to a TT protocol in controlling bone 
metabolic parameters in dialysis patients with secondary hyperparathyroidism over a 
23-week period. KDOQITM targets considered are: iPTH a300 pg/mL, calcium (Ca)  
9.5 mg/dL and phosphorus (P)  5.5 mg/dL. Resource utilization included the average 
dose per day, average duration of therapy, and cost per dose. The model compares 
the cost per patient who achieves target and the cost per week to maintain target, with 
the use of a combination of cinacalcet  TT relative to TT alone or no therapy. 
RESULTS: At the end of the study period, 30.2% (111) of patients receiving cinacalcet 
 TT achieved their KDOQITM targets, compared with 2.7% (5) for TT. The average 
cost per week of maintaining target was a349.10 for patients on cinacalcet  TT and 
a597.29 for patients on TT. The incremental cost per incremental week in target was 
a491.40 with TT compared with no therapy and was cost-saving (minus 39.68a per 
week) with cinacalcet  TT. The incremental cost per incremental patient at target 
after 23 weeks was a5,895.06 for patients receiving cinacalcet  TT compared with 
TT and a36,991.66 for patients receiving TT compared with no therapy. CONCLU-
SIONS: Patients administered cinacalcet  TT maintain, on average, KDOQITM targets 
longer than patients receiving TT and require less resources. This translates into lower 
costs per patient (compared with TT) to achieve and maintain KDOQITM targets. 1. 
Messa et al. Clin J Am Soc Nephrol. 2008;3:36–45.
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OBJECTIVES: Costing studies often do not identify the excess costs incurred by the 
health care system for patients with a disease vs. patients without the disease. Using 
cohort based cost estimates without controlling for costs also incurred by a non-
disease population can bias projections, long-term modeling and economic evaluation 
analyses. The objective of this study was to estimate the prevalence, total and excess 
costs attributable to diabetes and its complications in Ontario, Canada over 11 years 
(1995 to 2005). METHODS: Newly diagnosed type 1 and 2 diabetes cases aged 35 
and over were identiﬁed from the Ontario Diabetes Database and matched 1:2 using 
propensity scores with controls (non-diabetes cases). The following complications 
were identiﬁed: myocardial infarction, stroke, angina, heart failure, blindness in 1 eye, 
amputation, nephropathy and cataracts. Excess costs of diabetes were estimated as 
the difference between costs attributed to patients with diabetes vs. those attributed 
to patients without diabetes. RESULTS: The prevalence of diabetes rose drastically, 
from 6.5 to 10.5%. Excess costs were $2930 in the year of diabetes diagnosis and 
$1240 in subsequent years. In the year of an event, cost differences were greatest for 
patients with diabetes who had an amputation ($5133), followed closely by nephropa-
thy ($4117) and stroke cases ($3965). Excess costs were apparent for both females 
and males, and the cost amount was strongly associated with increasing age. CON-
CLUSIONS: Results demonstrate that relying on costs from a population with only 
the disease (i.e. diabetes) with no control can overestimate costs of the disease and 
associated complications. Assessing excess costs of disease is important for costing 
studies, longer-term modeling and economic evaluations in general. Existing studies 
which do not account for excess cost may overestimate cost and potentially bias esti-
mates of cost-effectiveness or cost savings due to effective patient management.
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OBJECTIVES: Stakeholders in Europe remain keenly interested in obtaining informa-
tion to help assess country-speciﬁc value of SMBG for patients with type-2 diabetes 
and treated with OADs. From national reimbursement system perspectives in France, 
Germany, and Spain, this study modeled the long-term (40-year) cost-effectiveness of 
SMBG at 1, 2, or 3x/day (vs. no SMBG) for this patient population. METHODS: 
SMBG input costs (strips, lancets, monitors, nurse training) were supplied by LifeScan 
in a2007 values and applied as appropriate for each country’s current reimbursement 
policy. Cohort characteristics and assumed HbA1c effects came from a U.S. Kaiser 
Permanente longitudinal analysis of new SMBG users. Country-speciﬁc complication 
costs obtained from published sources were inﬂated to a2007 values. Base-case out-
comes were discounted at 3% per annum for France and Germany; 6% for Spain. 
Sensitivity analyses varied time horizon (5, 10, 20 years) and discount rates relevant 
to each country. Sensitivity analyses also included a 0.036 dis-utility for SMBG in 
year 1. RESULTS: Incremental cost-effectiveness ratios (ICERs) were largest in France, 
where monitors were included as reimbursed SMBG acquisition costs. ICERs for 
SMBG 1x, 2x, and 3x/day were a12,114, a6,282, and a7,958, respectively. ICERs for 
SMBG 1 or 2x/day were a2,000 in Germany and a4,000 in Spain. ICERs for SMBG 
3x/day were a6000/QALY in both countries. Results were most sensitive to the 5-year 
time horizon. With the SMBG dis-utility, ICERs increased only modestly (a321– 
a2264/QALY) in all scenarios except SMBG 1/day in France, where it increased by 
a9578. CONCLUSIONS: With SMBG cost assumptions reﬂecting current payer reim-
bursement in France, Germany, and Spain, the use of SMBG was found to be cost-
effective. This study adds to the literature on the impact of assuming an SMBG 
dis-utility, and on the country-speciﬁc, long-term value of SMBG as a management 
tool for type-2 diabetes patients treated with OADs.
PDB23
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OBJECTIVES: Diabetes type 2 is a major health problem with severe complications 
and a signiﬁcant impact on quality of life. International guidelines, developed to 
provide better care and to prevent complications, are difﬁcult to translate into daily 
practice. Especially the lack of prevention of retinopathy and nephropathy through 
frequent screening are a current concern. The aim of this study is to assess the 
minimum impact a program at a pre-speciﬁed policy deﬁned cost, supporting general 
practitioners to put recommendations into daily clinical practice, has to achieve to be 
cost-effective. METHODS: We estimated the minimum number of patients, with a 
mean age of 65 years, that should be screened annually for respectively retinopathy 
and nephropathy, for the program at an implementation cost of a195 per patient, to  
be cost-effective. For both complications, a Markov model, adapted from published 
peer-reviewed models, was developed simulating the evolution of a patients cohort 
with type 2 diabetes over 25 years with cycles of 1 year. A public health care payer 
perspective in a Belgian setting was chosen. Transition probabilities were obtained 
from local epidemiological studies and published trials. Cost data of the different states 
were collected from literature and from the National Institute for Health and Disabil-
ity Insurance. Utility data for all states were obtained from published studies. A ratio 
of a30,000/QALY was used as threshold of willingness to pay for health gain. 
RESULTS: We found for nephropathy a net-saving cost of a6500/QALY when there 
is only an increase in annual screening of 10%. For retinopathy we found a net price 
of a1005 but no health gain. CONCLUSIONS: A scientiﬁc program in a Belgian 
setting with a given implementation cost of a195 per patient and a minimum increase 
in screening in the intervention group, would be cost-effective in the prevention of 
nephropathy and retinopathy.
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OBJECTIVES: The aim of this health economic analysis was to assess the cost-effec-
tiveness of biphasic insulin aspart (BIAsp) when switched from biphasic human insulin 
30 (BHI), based on type 2 diabetes patients from a prospective, multicentre, open 
label, non-controlled, observational, 24-week study. METHODS: A published and 
validated computer CORE Diabetes Model was used to project long-term economic 
and clinical outcomes in sub-cohort of type 2 diabetes patients treated with BIAsp 30 
versus BHI 30. The cohort had 831 (372 male) patients. There was HbA1C decrease 
